Generalized Anxiety Disorder Screener-7 (GAD-7)

1. Abstract

The Generalized Anxiety Disorder Screener-7 (GAD-7) is an internationally recognized, psychometrically robust, seven-item self-report questionnaire originally developed to screen for and evaluate the severity of generalized anxiety disorder (GAD) in ambulatory primary care settings. Designed by Robert L. Spitzer, Kurt Kroenke, Janet B. W. Williams, and Bernd Löwe in 2006, the instrument operationalizes the core diagnostic criteria of GAD outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) and retained in the DSM-5. Respondents rate the frequency of affective, cognitive, and psychomotor anxiety symptoms experienced over the preceding two weeks using a four-point Likert-type scale ranging from 0 (“Not at all”) to 3 (“Nearly every day”), generating a continuous composite score between 0 and 21.

Psychometric evaluations across diverse clinical and epidemiological cohorts consistently demonstrate excellent internal consistency (Cronbach’s α = .89–.92; McDonald’s ω > .90) and favorable test-retest reliability (interclass correlation coefficient / Pearson r = .83). Confirmatory factor analyses generally substantiate a unidimensional latent structure reflecting general anxiety distress, though bifactor and two-dimensional models delineating cognitive-emotional worry from somatic-vegetative tension have also been documented. Utilizing a clinical threshold of 10 points, the GAD-7 displays optimal diagnostic sensitivity (89%) and specificity (82%) against structured psychiatric interviews, while diagnostic meta-analyses identify thresholds between 7 and 10 as having exemplary diagnostic utility across distinct medical populations. Beyond GAD detection, the instrument exhibits strong convergent validity with established measures such as the Beck Anxiety Inventory (BAI) and the Symptom Checklist-90 (SCL-90), as well as moderate sensitivity in screening for comorbid panic disorder, social anxiety disorder, and post-traumatic stress disorder (PTSD). The GAD-7 is distributed in the public domain without licensing fees, establishing it as an indispensable standard in global clinical practice and empirical mental health research.

2. Keywords

Generalized Anxiety Disorder Screener-7, GAD-7, anxiety measurement, psychometrics, Patient Health Questionnaire, diagnostic screening, continuous symptom tracking, factor structure, receiver operating characteristic, primary care psychiatry, Beck Anxiety Inventory, measurement invariance.

3. Authors

The GAD-7 was formulated and validated through a collaborative clinical research initiative directed by prominent psychiatric epidemiologists and psychometricians:

• Robert L. Spitzer, M.D.: Department of Psychiatry, Columbia University College of Physicians and Surgeons, and the New York State Psychiatric Institute, New York, New York, USA. Dr. Spitzer served as the chief architect of the DSM-III and led the pioneering development of the Structured Clinical Interview for DSM (SCID) and the Primary Care Evaluation of Mental Disorders (PRIME-MD).
• Kurt Kroenke, M.D., MACP: Regenstrief Institute, Inc., and the Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Dr. Kroenke is a world-renowned internist and health services researcher specializing in physical-symptom epidemiology, chronic pain, and patient-reported outcome measures.
• Janet B. W. Williams, D.S.W.: Department of Psychiatry, Columbia University College of Physicians and Surgeons, and the New York State Psychiatric Institute, New York, New York, USA. Dr. Williams contributed extensively to the structural methodology of psychiatric classifications and standardized clinician-administered instruments.
• Bernd Löwe, M.D., Ph.D.: Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Dr. Löwe is an expert in psychosomatic medicine, cross-cultural psychometric adaptation, and somatic symptom disorders.

Correspondence regarding the foundational validation studies of the Patient Health Questionnaire family of screeners was historically maintained through the Regenstrief Institute and Columbia University. The instrument materials, manuals, and translations are managed openly via educational repositories and research foundations.

4. Purpose

The Generalized Anxiety Disorder Screener-7 was engineered to address a pervasive diagnostic blind spot in public health: the widespread underdetection and undertreatment of anxiety disorders in ambulatory general medicine. Epidemiological surveillance reveals that while generalized anxiety disorder represents one of the most prevalent psychiatric complaints in primary healthcare settings—displaying an estimated point prevalence ranging from 5% to 8%—clinicians fail to accurately diagnose or address it in up to two-thirds of clinical encounters. Historically, standardized diagnostic evaluations relied on lengthy clinician-administered interviews, such as the Structured Clinical Interview for DSM (SCID) or extensive multi-item inventories like the 21-item Beck Anxiety Inventory or the State-Trait Anxiety Inventory. The administrative burden of such scales (often exceeding 10 to 20 minutes) made universal screening impractical in time-constrained medical appointments.

To surmount these clinical workflow barriers, Spitzer and colleagues embarked on developing an efficient, ultra-brief, self-administered scale that preserved robust psychometric fidelity while requiring less than two minutes for a respondent to complete. The primary purpose of the GAD-7 is twofold: (1) to function as a sensitive, rapid clinical screening instrument that flags individuals who warrant an in-depth diagnostic clinical evaluation for GAD, and (2) to provide a standardized, continuous metric of anxiety symptom severity capable of tracking treatment response and longitudinal disease trajectory over time.

Although optimized for GAD, the clinical utility of the scale broadens into three ancillary areas. First, it serves as an effective initial screener for three other prominent anxiety conditions: panic disorder, social phobia, and post-traumatic stress disorder, which frequently co-occur with or manifest symptoms overlapping with generalized anxiety. Second, in clinical psychiatric settings, psychotherapy clinics, and clinical trials of psychopharmacological agents, the GAD-7 is widely deployed as an objective benchmark of therapeutic efficacy, tracking symptom remission, relapse, or treatment resistance across weekly cognitive behavioral therapy (CBT) sessions. Third, in broad epidemiological research and population health surveillance, the scale provides a uniform, cross-culturally validated measure to estimate the community-level burden of anxiety symptoms across diverse sociodemographic cohorts.

5. Psychological Construct

The GAD-7 is designed to capture the clinical construct of Generalized Anxiety Disorder as defined psychometrically and diagnostically. Pathological anxiety is distinguished from transient, adaptive stress by its chronicity, excessive intensity, irrational nature, uncontrollability, and broad generalization across diverse life contexts, such as health, finances, family wellbeing, and daily responsibilities.

The underlying construct operationalized by the GAD-7 spans two closely coupled dimensions: cognitive-affective apprehensive worry and somatic-motor physiological tension. The scale maps directly onto Criterion A and Criterion C of the DSM-IV/DSM-5 diagnostic taxonomy:

• Cognitive Apprehension and Metacognitive Uncontrollability (Items 1, 2, 3, and 7): Pathological worry is the central cognitive hallmark of GAD. The construct captures the subjective experience of affective arousal (“Feeling nervous, anxious, or on edge”), the perceived inability to regulate ruminative cognitive spirals (“Not being able to stop or control worrying”), the broad, pervasive scope of catastrophic ideation (“Worrying too much about different things”), and persistent hypervigilance characterized by anticipatory dread (“Feeling afraid, as if something awful might happen”). Psychometric inquiry demonstrates that the “uncontrollability” facet (Item 2) carries the highest discriminatory parameter in latent trait estimations, acting as the diagnostic core separating clinical pathology from subclinical non-pathological worry.
• Psychomotor Restlessness and Autonomic/Somatic Tension (Items 4, 5, and 6): The somatic dimension reflects prolonged autonomic arousal and musculoskeletal tension. This encompasses the subjective inability to down-regulate internal arousal states (“Trouble relaxing”), observable motor hyperactivity and inner physical agitation (“Being so restless that it is hard to sit still”), and emotional irritability precipitated by ongoing neurobiological strain and sleep fragmentation (“Becoming easily annoyed or irritable”).

In addition to the primary seven items assessing symptom frequency, the instrument incorporates a supplemental functional impairment index. This supplementary item asks respondents to quantify how difficult their symptoms have made it to fulfill occupational tasks, manage domestic responsibilities, or sustain interpersonal relationships. This operationalizes Criterion E of the DSM diagnostic framework, ensuring that statistical symptom elevation corresponds to measurable clinical and functional impairment in the respondent’s lived environment.

6. Theoretical Framework

The development and clinical interpretation of the GAD-7 are underpinned by several foundational psychological frameworks of anxiety pathology, cognitive vulnerability, and emotional regulation:

The Cognitive Avoidance Model of Worry

Pioneered by Thomas Borkovec and colleagues, the Cognitive Avoidance Theory conceptualizes worry as a predominantly verbal-linguistic, non-affective cognitive process that serves as a maladaptive coping mechanism. According to this framework, individuals prone to GAD generate continuous cognitive worst-case scenarios to mentally anticipate and prepare for perceived threats. By engaging in verbal-linguistic worry, they suppress catastrophic mental imagery and the profound physiological arousal associated with deeper, distressing emotional processing. The GAD-7 directly evaluates the chronic persistence of this avoidance mechanism through items measuring excessive, uncontrollable worrying across multiple life domains.

Metacognitive Theory of Psychological Vulnerability

Developed by Adrian Wells, Metacognitive Theory posits that pathological anxiety is sustained by distinct classes of beliefs about thought processes. Wells differentiates between “Type 1 worry” (worrying about external threats, physical health, and everyday events) and “Type 2 worry” or “meta-worry” (worrying about the nature and consequences of worry itself, such as believing that one’s worry is dangerous, uncontrollable, or indicative of imminent mental collapse). The GAD-7 specifically captures meta-worry through Item 2 (“Not being able to stop or control worrying”). The failure of metacognitive executive control represents the primary cognitive driver maintaining GAD chronicity, distinguishing patients with formal psychiatric disorders from the non-clinical general population.

Barlow’s Triple Vulnerability Model

David H. Barlow’s integrative model of anxiety etiology describes three overlapping risk domains: generalized biological vulnerability (heritable neurobiological hypersensitivity to stress), generalized psychological vulnerability (an early childhood sense of uncontrollable, unpredictable environmental stressors), and specific psychological vulnerability (conditioned learning that certain somatic or cognitive cues are directly life-threatening). The GAD-7 reflects the convergence of these vulnerabilities by measuring emotional hyper-reactivity, catastrophic expectation, and the physical manifestations of chronic stress reactivity.

7. Validity

The psychometric validity of the GAD-7 has been systematically evaluated across large-scale primary care trials, specialized psychiatric clinics, and community-based cross-cultural investigations.

Criterion and Diagnostic Validity

The foundational validation study by Spitzer et al. (2006) examined 2,740 ambulatory adult patients across 15 primary care clinics throughout the United States. Criterion validity was established by comparing self-reported GAD-7 scores against blinded, independent psychiatric evaluations conducted by trained mental health professionals using the Structured Clinical Interview for DSM-IV (SCID). Receiver Operating Characteristic (ROC) curve analyses yielded an Area Under the Curve (AUC) of 0.906 (95% CI: 0.882–0.930), indicating exceptional discriminatory precision.

At the standard recommended cut-off score of 10, the GAD-7 demonstrated a sensitivity of 89% and a specificity of 82% for diagnosing generalized anxiety disorder. In a large systematic review and diagnostic meta-analysis of 11 studies incorporating 4,115 individuals, Plummer, Manea, Trepel, and McMillan (2016) demonstrated that cut-offs between 7 and 10 yielded acceptable psychometric properties, with a score of 8 exhibiting optimal balance between sensitivity (0.83; 95% CI, 0.71–0.91) and specificity (0.84; 95% CI, 0.70–0.92). In secondary clinical screenings, a cut-off score of 10 identified panic disorder (sensitivity 74%, specificity 81%), social anxiety disorder (sensitivity 72%, specificity 80%), and PTSD (sensitivity 66%, specificity 81%) (Kroenke et al., 2007).

Convergent and Discriminant Validity

Convergent validity has been repeatedly substantiated through strong linear correlations with established multi-item anxiety rating scales. The GAD-7 correlates strongly with the Beck Anxiety Inventory (r = .72), the anxiety subscale of the Symptom Checklist-90 (SCL-90; r = .74), the Hospital Anxiety and Depression Scale–Anxiety subscale (HADS-A; r = .75 to .82), and the State-Trait Anxiety Inventory–Trait scale (STAI-T; r = .73 to .78).

Discriminant validity assessments reveal that while GAD-7 scores correlate moderately with depression measures—such as the Patient Health Questionnaire-9 (PHQ-9) (r = .65 to .75)—this elevation mirrors empirical psychiatric comorbidity rather than psychometric collinearity. Confirmatory factor models testing a two-factor structure (anxiety vs. depression) consistently outperform single-factor constructs when GAD-7 and PHQ-9 items are modeled simultaneously. Furthermore, the GAD-7 displays lower correlations with generalized physical symptom clusters (PHQ-15; r = .40–.52) and health-related quality of life inventories (SF-36 Mental Health r = -.68; SF-36 Physical Functioning r = -.23), demonstrating robust construct specificity.

8. Reliability

The GAD-7 exhibits high reliability across diverse patient populations, clinical formats, and cultural settings.

Internal Consistency

In the original primary care derivation cohort of 2,740 patients (Spitzer et al., 2006), the instrument demonstrated high internal consistency, with a Cronbach’s alpha coefficient of α = .92. Subsequent international psychometric investigations have replicated these parameters:

• Spanish validation in primary healthcare (García-Campayo et al., 2010): α = .936.
• Portuguese primary care evaluation (Sousa et al., 2015): α = .88.
• German general population normative cohort (Löwe et al., 2008): α = .89.
• Acute psychiatric inpatient sample (Kertz, Bigda-Peyton, & Björgvinsson, 2013): α = .89.

Across these investigations, McDonald’s omega total (ω_t) and omega hierarchical (ω_h) regularly exceed .90 and .82 respectively, verifying that scale scores represent a reliable, coherent measurement of a single dominant psychological attribute without excessive item redundancy.

Test-Retest Reliability and Measurement Error

Temporal stability was evaluated by re-administering the GAD-7 to a sub-cohort of stable primary care patients over a one- to two-week interval via telephone and paper-based protocols. The test-retest reliability coefficient was r = .83, demonstrating solid consistency in symptom reporting in the absence of therapeutic intervention. The standard error of measurement (SEM) has been calculated across multiple clinical studies between 1.5 and 2.1 points on the 0–21 total scale.

Based on these psychometric properties, the Reliable Change Index (RCI) is established at approximately 4 points. Thus, a change of 4 points or more across repeated administrations in a clinical or trial context represents true, statistically meaningful symptom change beyond the margin of measurement error (with 95% statistical confidence). This establishes the scale’s sensitivity to change in response to pharmacological and psychological interventions.

9. Factor Analysis

The structural dimensionality of the GAD-7 has been investigated using both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA) across medical, psychiatric, and non-clinical community cohorts worldwide.

Original Unidimensional Model

In the initial developmental phase, Spitzer et al. (2006) evaluated an initial pool of 13 candidate items. Principal axis factoring with promax rotation supported the reduction of the inventory to seven high-performing items that loaded onto a single dominant factor accounting for 48.6% of the total variance. Factor loadings for all individual items were uniform and substantial, ranging from .69 to .81:

• Item 1 (Feeling nervous/anxious/on edge): λ = .81
• Item 2 (Uncontrollable worrying): λ = .80
• Item 3 (Worrying too much): λ = .78
• Item 4 (Trouble relaxing): λ = .73
• Item 5 (Restless/hard to sit still): λ = .69
• Item 6 (Easily annoyed/irritable): λ = .70
• Item 7 (Afraid awful might happen): λ = .74

Two-Factor and Bifactor Formulations

While the single-factor structure is broadly accepted for clinical scoring, several large-scale CFA studies in specialized populations have documented superior statistical fit for a two-dimensional oblique model or a bifactor construct:

• Cognitive-Emotional Factor (Items 1, 2, 3, 7): Reflects core apprehensive worry, anticipatory anxiety, and metacognitive uncontrollability.
• Somatic-Symptom Factor (Items 4, 5, 6): Encapsulates physical motor tension, restlessness, and emotional irritability.

In these models, the correlation between the cognitive and somatic latent factors typically ranges between .75 and .88, suggesting substantial overlap. Fit indices for the unidimensional versus bifactor configurations in contemporary CFA studies frequently demonstrate that while a single general anxiety factor captures the vast majority of common variance (Explained Common Variance; ECV > .75–.80), allowing residual correlations among the somatic items (Items 4, 5, and 6) yields excellent model fit parameters: Comparative Fit Index (CFI) > .97, Tucker-Lewis Index (TLI) > .96, and Root Mean Square Error of Approximation (RMSEA) ≤ .055.

Measurement Invariance

Multigroup confirmatory factor analyses have established measurement invariance (configural, metric, and scalar) across biological sex, age brackets (adolescents vs. working-age adults vs. geriatric populations), socioeconomic strata, and language translations (e.g., English, Spanish, German, Mandarin, Arabic). This confirms that variations in GAD-7 scores reflect genuine differences in latent anxiety severity rather than differential item functioning or cultural response biases.

10. Instrument / Measurement Tool

The GAD-7 is an ultra-brief, standardized patient-reported outcome measure (PROM) designed for self-administration or clinical interview formats.

• Test Type: Self-administered psychological screening and symptom-severity monitoring inventory; also amenable to clinician-facilitated administration.
• Target Population: Adolescents (ages 12–17) and adults (ages 18 and older) in primary medical care, outpatient psychiatric clinics, counseling centers, and community health settings.
• Recall Period: The past two weeks (14 days).
• Item Count: 7 core symptom items, plus 1 optional supplemental functional impairment item.
• Response Format: 4-point Likert-type frequency scale:
  • 0 = Not at all
  • 1 = Several days
  • 2 = More than half the days
  • 3 = Nearly every day
• Scoring and Scoring Rules:
  • All 7 items are scored from 0 to 3 in a positive direction (there are no reverse-scored items).
  • The total composite score is derived by calculating the direct mathematical sum of all 7 items, yielding a continuous range from 0 to 21.
  • Severity Cut-Off Scores:
    • 0–4: Minimal or no anxiety symptoms
    • 5–9: Mild anxiety symptoms
    • 10–14: Moderate anxiety symptoms
    • 15–21: Severe anxiety symptoms
  • Diagnostic Threshold: A composite score of 10 or greater is the validated benchmark cut-point signifying a screen-positive result for probable Generalized Anxiety Disorder, recommending subsequent structured psychiatric clinical evaluation.
  • Supplemental Functional Item: “If you checked off any problems, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?” Rated on a 4-point qualitative scale (Not difficult at all, Somewhat difficult, Very difficult, Extremely difficult). This item measures real-world functional impairment; it is evaluated qualitatively and is not added to the 0–21 total symptom score.
• Completion Time: Approximately 1 to 2 minutes.

11. Permissions & Fee and Test Year

The Generalized Anxiety Disorder Screener-7 was officially published in 2006 by Robert L. Spitzer, Kurt Kroenke, Janet B. W. Williams, and Bernd Löwe in the Archives of Internal Medicine (now JAMA Internal Medicine). The instrument was conceived and validated as an integral part of the broader Patient Health Questionnaire (PHQ) diagnostic assessment framework.

The development of the PHQ family was supported in part by an educational grant from Pfizer Inc. However, the creators and copyright holders dedicated the GAD-7, PHQ-9, and associated instruments to the public domain to maximize their utility for clinical practice and public health. As a result, the GAD-7 is completely free of charge for both clinical and academic research purposes. No formal licensing agreements, permissions, or royalty fees are required to reproduce, translate, administer, score, or integrate the instrument into digital electronic medical record (EMR) systems or research protocols, provided the original academic authors and citations are appropriately credited.

Authorized clinical copies, manuals, scoring keys, and validated translations into more than 80 languages are hosted freely through academic screening initiatives and the public PHQ Screeners repository.

12. References

Below are primary peer-reviewed references and foundational psychometric literature concerning the GAD-7:

• Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988). An inventory for measuring clinical anxiety: Psychometric properties. Journal of Consulting and Clinical Psychology, 56(6), 893–897. https://doi.org/10.1037/0022-006X.56.6.893
• Daig, I., Herschbach, P., Lehmann, A., Knoll, N., & Decker, O. (2009). Gender and age differences in domain-specific life satisfaction and the impact of depressive and anxiety symptoms: A general population survey from Germany. Quality of Life Research, 18(6), 669–678. https://doi.org/10.1007/s11136-009-9481-3
• Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H., & Covi, L. (1974). The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behavioral Science, 19(1), 1–15. https://doi.org/10.1002/bs.3830190102
• Farrand, P., & Woodford, J. (2013). Measurement of individualised quality of life amongst young people with indicated personality disorder during emerging adulthood using the SEIQoL-DW. Quality of Life Research, 22(4), 829–838. https://doi.org/10.1007/s11136-012-0210-y
• García-Campayo, J., Zamorano, E., Ruiz, M. A., Pardo, A., Pérez-Páramo, M., López-Gómez, V., Freire, O., & Rejas, J. (2010). Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool. Health and Quality of Life Outcomes, 8, Article 8. https://doi.org/10.1186/1477-7525-8-8
• Johnson, J. G., Harris, E. S., Spitzer, R. L., & Williams, J. B. (2002). The patient health questionnaire for adolescents: Validation of an instrument for the assessment of mental disorders among adolescent primary care patients. Journal of Adolescent Health, 30(3), 196–204. https://doi.org/10.1016/S1054-139X(01)00333-0
• Kertz, S., Bigda-Peyton, J., & Björgvinsson, T. (2013). Validity of the Generalized Anxiety Disorder-7 scale in an acute psychiatric sample. Clinical Psychology & Psychotherapy, 20(5), 456–464. https://doi.org/10.1002/cpp.1802
• Kroenke, K., Spitzer, R. L., Williams, J. B., Monahan, P. O., & Löwe, B. (2007). Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Annals of Internal Medicine, 146(5), 317–325. https://doi.org/10.7326/0003-4819-146-5-200703060-00004
• Löwe, B., Decker, O., Müller, S., Brähler, E., Schellberg, D., Herzog, W., & Herzberg, P. Y. (2008). Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Medical Care, 46(3), 266–274. https://doi.org/10.1097/MLR.0b013e318160d093
• Mills, S. D., Fox, R. S., Malcarne, V. L., Roesch, S. C., Champagne, B. R., & Sadler, G. R. (2014). The psychometric properties of the Generalized Anxiety Disorder-7 scale in Hispanic Americans with English or Spanish language preference. Cultural Diversity and Ethnic Minority Psychology, 20(3), 463–468. https://doi.org/10.1037/a0036523
• Plummer, F., Manea, L., Trepel, D., & McMillan, D. (2016). Screening for anxiety disorders with the GAD-7 and GAD-2: A systematic review and diagnostic meta-analysis. General Hospital Psychiatry, 39, 24–31. https://doi.org/10.1016/j.genhosppsych.2015.11.005
• Sousa, T. V., Viveiros, V., Chai, M. V., Vicente, F. L., Jesus, G., Carnot, M. J., Barbosa, M. A., & Ferreira, P. L. (2015). Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale. Health and Quality of Life Outcomes, 13, Article 50. https://doi.org/10.1186/s12955-015-0244-2
• Spitzer, R. L., Kroenke, K., & Williams, J. B. (1999). Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. JAMA, 282(18), 1737–1744. https://doi.org/10.1001/jama.282.18.1737
• Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092–1097. https://doi.org/10.1001/archinte.166.10.1092
• Spitzer, R. L., Williams, J. B., Kroenke, K., Hornyak, R., & McMurray, J. (2000). Validity and utility of the PRIME-MD Patient Health Questionnaire in assessment of 3000 obstetric-gynecologic patients: The PRIME-MD Patient Health Questionnaire Obstetrics-Gynecology Study. American Journal of Obstetrics and Gynecology, 183(3), 759–769. https://doi.org/10.1067/mob.2000.106580
• Spitzer, R. L., Williams, J. B., Kroenke, K., Linzer, M., deGruy, F. V., 3rd, Hahn, S. R., Brody, D., & Johnson, J. G. (1994). Utility of a new procedure for diagnosing mental disorders in primary care: The PRIME-MD 1000 study. JAMA, 272(22), 1749–1756. https://doi.org/10.1001/jama.1994.03520220043029

13. Items of the Scale (Questionnaire)